Kliniczny Oddział Neurologii Samodzielnego Szpitala Klinicznego nr 1, ul. 3 Maja 13/15, 41-800 Zabrze.
Neurol Neurochir Pol. 2013 Mar-Apr;47(2):126-30. doi: 10.5114/ninp.2013.34730.
The aim of this study was to evaluate the concentration of 25(OH)D₃ and the indices of calcium and phosphorus metabolism at different times of relapsing-remitting multiple sclerosis (MS). The relationships between the concentrations of 25(OH)D₃ and the indices of calcium-phosphate metabolism were determined, depending on the duration of disease and vitamin and unsaturated fatty acids supplementation.
Thirty patients (15 at the early stage and 15 at the advanced stage of MS) were enrolled. Each patient underwent neurological examination; neurological motor disability was defined according to the Expanded Disability Status Scale (EDSS). The results were compared to the values obtained in the control group (15 individuals) selected according to the age of subjects, their residence, ethnicity and gender.
Significantly lower serum concentrations of 25(OH)D₃ in MS patients compared to the control group were found. MS patients at the advanced stage of the disease (duration of 5-6 years) had lower 25(OH)D₃ concentrations than patients at the early stage of MS. Among patients in an advanced stage of MS, significantly lower levels of 25(OH)D₃ were found in women compared to men with a similar level of physical disability.
Lower serum concentrations of 25(OH)D₃ in MS patients compared to the control group were found. The lowest concentrations of 25(OH)D₃ were found in female patients aged 20-40 and in patients with a longer disease duration without substantial impairment of calcium-phosphate metabolism.
本研究旨在评估不同缓解-复发多发性硬化(MS)时期的 25(OH)D₃浓度以及钙磷代谢指标。根据疾病持续时间和维生素及不饱和脂肪酸的补充情况,确定了 25(OH)D₃浓度与钙磷代谢指标之间的关系。
共纳入 30 例患者(MS 早期 15 例,晚期 15 例)。每位患者均进行神经学检查;根据扩展残疾状况量表(EDSS)定义神经运动功能障碍。结果与根据年龄、居住地、种族和性别选择的对照组(15 人)进行比较。
与对照组相比,MS 患者血清 25(OH)D₃浓度明显降低。疾病晚期(病程 5-6 年)的 MS 患者 25(OH)D₃浓度低于疾病早期的 MS 患者。在晚期 MS 患者中,女性患者的 25(OH)D₃水平明显低于具有相似身体残疾水平的男性患者。
与对照组相比,MS 患者的血清 25(OH)D₃浓度降低。在 20-40 岁的女性患者和疾病持续时间较长但钙磷代谢无明显受损的患者中,25(OH)D₃的浓度最低。